Immunoglobulin E specific to Alnus incana subsp. rugosa pollen allergens (IgE (Alnus incana subsp. rugosa))

Immunoglobulin E (IgE) specific to Alnus incana subsp. rugosa (Speckled Alder) pollen allergens is a key mediator in the development of seasonal allergic diseases. These antibodies are produced by B cells upon sensitization to allergens such as Aln g 1, which is a major allergen in alder pollen and a member of the PR-10 protein family. When an individual is re-exposed to the pollen, these specific IgE molecules, which are bound to high-affinity receptors (FcεRI) on mast cells and basophils, cross-link with the allergen. This cross-linking triggers the release of inflammatory mediators like histamine and leukotrienes, resulting in symptoms of allergic rhinitis and asthma. Therapeutic strategies targeting these IgE molecules include monoclonal antibodies like Omalizumab, which sequester free IgE, and allergen-specific immunotherapy (AIT), which aims to desensitize the immune system to the specific Alnus allergens. Understanding the specificity of these antibodies is crucial due to high cross-reactivity among the Betulaceae family, including birch and hazel pollens.

Other names

Speckled alder pollen-specific IgETag alder pollen-specific IgEAlnus rugosa specific IgEGrey alder pollen-specific IgEAnti-Aln g IgE

Anti-IgE monoclonal antibodies like Omalizumab bind to the Cε3 domain of the IgE molecule, preventing it from binding to the high-affinity IgE receptor (FcεRI) on mast cells and basophils. Allergen-specific immunotherapy (AIT) works by inducing immune tolerance through the administration of increasing doses of the specific allergen, leading to a shift from a Th2 to a Th1 immune response and the production of IgG4 blocking antibodies.